Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Judith Michels; Ilio Vitale; Laura Senovilla; David P. Enot; Pauline Garcia; Delphine Lissa; Ken A. Olaussen; Catherine Brenner; Jean Charles Soria; Maria Castedo; Guido Kroemer

ArticleOPEN ACCESS

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Michels J
Vitale I
Senovilla L
et al.

Cell Cycle

DOI: 10.4161/cc.24034

64Citations

50Readers

Get full text

Abstract

Abbreviations: CDDP, cisplatin; CEP, CEP 8983; DiOC6(3), 3′-dihexyloxacarbocyanine iodide; Δψm, mitochondrial transmembrane potential; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NSCLC, non-small cell lung carcinoma; PARP, poly(ADP-ribose) polymerase; PI, propidium iodide; PJ, PJ34 hydrochloride hydrate; siRNA, small-interfering RNA. © 2013 Landes Bioscience.

Author supplied keywords

A549 cells
Apoptosis
CEP 8983
DNA damage response
PJ34 hydrochloride
Small-interfering RNAd

Cite

CITATION STYLE

APA

Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., … Kroemer, G. (2013, March 15). Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle. Taylor and Francis Inc. https://doi.org/10.4161/cc.24034

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Abstract

Author supplied keywords

Cite

Register to see more suggestions